Clinical resolution · patients with otomycosis
It is very uncertain whether clotrimazole changes complete clinical resolution compared with another azole (very low certainty).
1 finding from 1 review
Significant adverse events · patients with otomycosis
1 finding from 1 review
Mycological resolution · patients with otomycosis
Clotrimazole showed no clear difference in mycological resolution compared with another azole (low certainty).
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether specific antipsychotic changes tardive dyskinesia: not improved to a clinically important extent compared with other drugs (very low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether specific antipsychotic changes tardive dyskinesia: deterioration of symptoms compared with other drugs (very low certainty).
1 finding from 1 review
Mental state ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effect: any ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effect: extrapyramidal symptoms ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether specific antipsychotic changes acceptability of the treatment: leaving the study early compared with other drugs (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Overall survival† · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to lower overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.42 [0.37, 0.48]
418 participants
High
Overall survival† · people with cutaneous melanoma
BRAF inhibitors leads to lower overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.4 [0.28, 0.57]
925 participants
High
Progression‐free survival · people with cutaneous melanoma
BRAF inhibitors leads to lower progression‐free survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.27 [0.21, 0.34]
925 participants
High
Tumour response · people with cutaneous melanoma
BRAF inhibitors leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
RR 6.78 [4.84, 9.49]
925 participants
High
Progression‐free survival · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.49 [0.39, 0.61]
957 participants
Moderate
Toxicity (≥ G3) · people with cutaneous melanoma
BRAF inhibitors showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).
1 finding from 1 review
RR 1.27 [0.48, 3.33]
408 participants
Low
Overall survival† · people with cutaneous melanoma
MEK inhibitors showed no clear difference in overall survival† compared with chemotherapy (low certainty).
1 finding from 1 review
HR 0.85 [0.58, 1.25]
496 participants
Low
Progression‐free survival · people with cutaneous melanoma
MEK inhibitors probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.58 [0.42, 0.8]
496 participants
Moderate
Tumour response · people with cutaneous melanoma
MEK inhibitors leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
RR 2.01 [1.35, 2.99]
496 participants
High
Toxicity (≥ G3) · people with cutaneous melanoma
MEK inhibitors probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.61 [1.08, 2.41]
91 participants
Moderate